FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s – 16 or 15d – 16
of
the Securities Exchange Act of 1934
For the month of March 2005
Acambis plc
(Translation of registrant’s name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether
the registrant files or will file annual reports under cover of
Form 20-F or Form 40-F).
Forms 20-F Form 40-F
(Indicate by check mark whether
the registrant by furnishing the information contained in this Form is
also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No
(If Yes is marked,
indicate below the file number assigned to the registrant in connection with
Rule 12g3-2(b): 82- ).
Enclosure:
Schedule 10 Notification of Major Interests in
Shares.
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc |
2. Name of shareholder having a major interest
Fidelity International Limited (FIL) (and its direct and indirect subsidiaries incorporating Fidelity Investment Services Limited (FISL)) and Mr Edward C Johnson 3d |
3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18
As above |
4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them
JP Morgan, Bournemouth 191,068 shares*** |
5. Number of shares / amount of stock acquired
N/a |
6. Percentage of issued class
N/a |
7. Number of shares / amount of stock disposed
Not disclosed |
8. Percentage of issued class
Not disclosed |
9. Class of security
Ordinary shares of 10p each |
10. Date of transaction
Not disclosed |
11. Date company informed
22 March 2005 |
12. Total holding following this notification
4,267,697 ordinary shares |
13. Total percentage holding of issued class following this notification
3.98% |
14. Any additional information
N/a |
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary +44 (0) 1223 275 300 |
16. Name and signature of authorised company official responsible for making this notification
Elizabeth Brown |
Date of notification
23 March 2005 |
The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant Peptide Therapeutics Group has duly
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Date: 24 March 2005 | ACAMBIS PLC | |
By: | /s/ Lyndsay Wright | |
Name: Lyndsay Wright | ||
Title: Director of Communications |